Cargando…

Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review

Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinter, Andreas, Bonnekoh, Bernd, Hadshiew, Ina Marion, Zimmer, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628099/ https://www.ncbi.nlm.nih.gov/pubmed/31372022 http://dx.doi.org/10.2147/CCID.S211938

Ejemplares similares

Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
por: Fargnoli, Maria Concetta, et al.
Publicado: (2023)

Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis
por: Coimbra, Susana, et al.
Publicado: (2014)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
por: Pinter, Andreas, et al.
Publicado: (2018)

Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: A case report
por: Yeung, Jensen, et al.
Publicado: (2020)

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
por: Roman, Michael, et al.
Publicado: (2017)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab
por: Lambert, Jo, et al.
Publicado: (2021)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials
por: Farahnik, Benjamin, et al.
Publicado: (2016)

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States
por: Feldman, Steven R., et al.
Publicado: (2018)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
por: Menter, Alan, et al.
Publicado: (2020)

Brodalumab in psoriasis: evidence to date and clinical potential
por: Foulkes, Amy C, et al.
Publicado: (2019)

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
por: Gottlieb, Alice, et al.
Publicado: (2020)

Clinical potential of brodalumab in the management of psoriasis: the evidence to date
por: Sandoval, Laura F, et al.
Publicado: (2015)

Protocol for the safety of brodalumab regarding psychiatric comorbidities in patients with psoriasis
por: Pikou, O., et al.
Publicado: (2022)

Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis
por: Menter, Alan, et al.
Publicado: (2022)

Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: A Narrative Review
por: Cannizzaro, Maria Vittoria, et al.
Publicado: (2023)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton, Philip, et al.
Publicado: (2021)

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study
por: Seo, Seong Jun, et al.
Publicado: (2020)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Long-Term Treatment with Dimethyl Fumarate for Plaque Psoriasis in Routine Practice: Good Overall Effectiveness and Positive Effect on Impactful Areas
por: Augustin, Matthias, et al.
Publicado: (2022)

Two Cases of Treatment of Moderate to Severe Acne with an Acupuncture-Debridement Microsurgical Technique and Review of the Literature
por: Jia, Renchuan, et al.
Publicado: (2023)

Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis
por: Elgaard, Cathrine Dawn Büttner, et al.
Publicado: (2023)

Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
por: REICH, Kristian, et al.
Publicado: (2022)

Severe Psoriasis Successfully Treated with Brodalumab after Eradication of Hepatitis C Virus with Glecaprevir and Pibrentasvir: A Case Report
por: Ito, Michiko, et al.
Publicado: (2021)

Brodalumab in the treatment of psoriatic arthritis – the latest reports
por: Banaszczyk, Katarzyna
Publicado: (2021)

Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet’s syndrome: case series and literature review
por: Liu, Jinjing, et al.
Publicado: (2020)

The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature
por: Rutkowski, David, et al.
Publicado: (2019)

Effectiveness of Long-Term Treatment with Brodalumab on Anxiety or Depressive Symptoms in Japanese Patients with Psoriasis: The ProLOGUE Study
por: Ohata, Chika, et al.
Publicado: (2023)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
por: Lebwohl, Mark G., et al.
Publicado: (2019)

Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series
por: Hosono, Shusaku, et al.
Publicado: (2020)

Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature
por: Doan, Serge, et al.
Publicado: (2016)

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory
por: Gordon, KB, et al.
Publicado: (2014)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Ustekinumab-induced remission of recalcitrant guttate psoriasis: A case series
por: Brummer, Grace C., et al.
Publicado: (2017)

Eczematous reactions to psoriasis biologics treated with dupilumab: A case series
por: Koschitzky, Merav, et al.
Publicado: (2021)

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
por: Mayor Ibarguren, Ander, et al.
Publicado: (2021)

Apatinib successfully administered in malignant tumour patients with severe hypotension: a case series, literature review, and considerations for treatment
por: Chen, Haiming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7op1lbmpotfv9li5fgmfsvhdls